Form 4: Integra Lifesciences Insider Trades Common Stock

Jeffrey Mosebrook, SVP of Integra Lifesciences, reported a transaction involving the acquisition of common stock.

Summary

• Jeffrey Mosebrook, Senior Vice President and Principal Accounting Officer at Integra Lifesciences Holdings Corp. (IART), reported a transaction on July 1, 2026.
• Mosebrook acquired 937 shares of common stock at a price of $17.89 per share.
• Following this transaction, Mosebrook beneficially owns 34,516 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing due to an insider buying shares, which can indicate confidence, but the transaction itself is routine disclosure.

Positives

• Insider acquisition of company stock can signal confidence in the company's future prospects.
• The transaction involved a direct purchase, indicating personal investment by a key executive.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the life sciences sector, providing transparency into executive investment decisions.

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive signal of management's belief in the company's value.
• Employees: May interpret the purchase as a sign of executive confidence, potentially boosting morale.
• Creditors: No direct impact is indicated by this transaction.

Key Dates

Keywords

Form 4, Insider Trading, Beneficial Ownership, Integra Lifesciences, IART, Common Stock, Securities Exchange Act